Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
163
resultados
Última actualización
02/08/2026 [07:30:00]
Resultados 125 a 150 de 163
Resumen de: US20260166145A1
The present disclosure provides methods for preventing or treating Alzheimer's disease in a subject, and/or reducing the likelihood or severity of Alzheimer's disease comprising administering to the subject an effective amount of an anti-CD33 antibody or an antigen binding fragment thereof. Alternatively, the methods comprise administering to the subject an effective amount of engineered immune cells expressing a neuronal antigen specific CAR and an anti-CD33 antibody or an antigen binding fragment thereof.
Resumen de: US20260166181A1
0000 The present disclosure relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and delivery methods for the treatment of spinal cord related disorders including ALS.
Resumen de: US20260166006A1
0000 The present disclosure relates to methods of treating neurological diseases, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound or pharmaceutical composition according to any embodiment described herein. The present disclosure relates to the methods of treating Parkinson's disease and Dementia with Lewy Bodies, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound or pharmaceutical composition according to any embodiment described herein.
Resumen de: WO2025038406A1
A series of non-peptide mu opioid receptor (MOR) selective modulators is provided. The compounds have the general formula (I) where R is (II) and where one of a, b, c, d, e or f is the point of attachment of indole ring R to the epoxymorphinan skeleton; at least one of the atoms at positions a, b, c, d, e and f is N; the remaining atoms at positions at a, b, c, d, e and f are CH; and * is a chiral carbon. The compounds are generally MOR antagonists and are used to treat disorders related to opioid receptor functions such as opioid addiction and opioid overdose, for the treatment of neurological diseases and for the treatment of pain, without causing constipation.
Resumen de: EP4759364A2
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SNCA mRNA in a cell or animal, and in certain instances reducing the amount of alpha-synuclein protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include motor dysfunction, aggregation of alpha-synuclein, neurodegeneration, cognitive decline and dementia. Such neurodegenerative diseases include Parkinson's disease, dementia with Lewy bodies, diffuse Lewy body disease, pure autonomic failure, multiple system atrophy, neuronopathic Gaucher's disease and Alzheimer's disease.
Resumen de: KR20260090995A
본 발명은 스리랑카산 계피로부터 알츠하이머성 치매 치료에 유효한 유효 물질(유제놀, 신남알데하이드)을 추출할 수 있어, 저비용으로 독성 성분인 쿠마린이 적은 알츠하이머성 치매 치료에 유효한 스리랑카산 계피 유래 유효 물질을 획득할 수 있는 효과를 제공하는 발명으로, 추출 단계(S100), 용매 분획 단계(S200), 정제 단계(S300)를 포함하여 구성되는 것을 특징으로 한다.
Resumen de: WO2026122090A1
Embodiments of the invention include a system and method of using biomarkers in the diagnosis of Alzheimer's disease. A subject can be screened for Alzheimer's disease based on altered expression of one or more biomarkers in blood, plasma or saliva from the subject. Embodiments include 43 specific mRNA biomarkers to screen or distinguish healthy individuals from individuals affected with Alzheimer's disease. The biomarkers can also be used to determine the prognosis of a subject with the disease and identify early-onset and/or asymptomatic Alzheimer's disease.
Resumen de: WO2026119142A1
The present invention belongs to the technical field of medicine. Specifically disclosed are a compound represented by formula I, and a use thereof. The compound of the present invention has a structure represented by formula I, the definitions of each group and substituent being as described in the description. The compound of the present invention can be used for the treatment or prevention of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, progressive multiple sclerosis, amyotrophic lateral sclerosis, dry age-related macular degeneration, and the like.
Resumen de: US20260159559A1
0000 A method of treating Alzheimer's Disease (AD) is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which prevents the binding of amyloid precursor protein (APP) to Tau protein.
Resumen de: US20260158002A1
An application of a composition in improving or treating cognitive impairment. The composition contains 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharmaceutically acceptable salt thereof and borneol or dexborneol. The cognitive impairment comprises Alzheimer's disease (AD), vascular dementia (VD), mild cognitive impairment (MCI), and other types of dementia.
Resumen de: WO2026118416A1
Provided are an antibody that targets a P-Tau181 protein, or an antigen-binding fragment thereof and the use thereof. The provided antibody can specifically recognize and bind to the P-Tau181 protein, and does not recognize p-Tau217 and non-phosphorylated Tau proteins, and therefore can be used for preparing detection formulations or kits for diagnosing p-Tau181 protein-related diseases, such as Alzheimer's disease.
Resumen de: US20260158142A1
Provided are engineered cells that include a T cell receptor (TCR) or antigen-binding fragment thereof that binds to amyloid beta, and methods of engineering and using such cells, such as in methods of treatment, diagnosis, and monitoring of therapeutic effectiveness, of diseases or conditions, such as those associated with amyloid beta, e.g., Alzheimer's Disease.
Resumen de: WO2026117926A1
Provided is new use of the compound represented by formula (I). The compound represented by formula (I) has excellent anti-inflammatory activity, can effectively inhibit the activity of galectin-3, reduce neuroinflammatory responses, improve cognitive function, reduce the overactivation of microglia, reduce the deposition of Aβ, and palliate synaptic degeneration, and is used for treating Alzheimer's disease.
Resumen de: WO2026118958A1
The present application relates to an hM4Di mutant and the use thereof in the preparation of a drug for treating Parkinson's disease. Compared with wild-type hM4Di, the hM4Di mutant comprises one or more of amino acid mutations Y439A, Y439G, W435A or W435G. The use comprises the use of an AAV expression vector containing a polynucleotide encoding the hM4Di mutant and an hSyn promoter, in combination with clozapine-N-oxide, in the preparation of a drug for treating Parkinson's disease.
Resumen de: US20260158046A1
Provided herein are methods of treating a neurodegenerative disorder (e.g., Parkinson's Disease) or a symptom thereof in a patient, by administering to the patient doxycycline (or a pharmaceutically acceptable salt thereof) either alone or in combination with other therapeutic agents (e.g., levodopa).
Resumen de: WO2026122407A1
Abeta binders are provided, as well as related polynucleotides, vectors, host cells, methods of production, compositions (e.g., pharmaceutical compositions), uses, and methods of use, e.g., for treatment of Alzheimer's disease.
Resumen de: WO2026122681A1
Aspects of the present disclosure relate, at least in part, to the creation of a human induced pluripotent stem cell line that can be induced to various brain cell types to be used for high throughput drug screens for agents that reduce lipid burden and AD related pathological features. The disclosure also provides details on several compounds that are useful for treating neurodegenerative diseases such as Alzheimer's disease.
Resumen de: EP4755391A1
0001 Neurological disorders, Parkinson's disease and Multiple System Atrophy (MSA) cause serious socio-economic problems as there are, at present only therapies that treat the symptoms. Parkinson's research is a highly competitive field focusing on the specific drug targeting of the aggregation of alpha-synuclein (SYN). The discovery of Tubulin Polymerization Promoting Protein (TPPP) was a crucial factor in anti-Parkinson research. TPPP is a prominent pathological partner of SYN, which shifts the SYN-SYN aggregation toward the formation of fatal SYN-TPPP assemblies. The disassembly of the SYN-TPPP by specific agents may eliminate the toxicity of the pathological assembly of SYN by the proteolytic degradation of the excess SYN and leads to the recovery of the physiologically active proteins.
Resumen de: WO2025031917A1
The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
Resumen de: US2025059165A1
0000 The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
Resumen de: WO2026114055A1
Provided are a hydroxymethyltransferase and a use of a cofactor or metabolic substrate thereof in preparation of drugs for treating neurodegenerative diseases. Specifically, a hydroxymethyl transfer reaction is performed on glycine residues in protein aggregates such as Poly-GA, Poly-GR, and TDP-43 by means of serine hydroxymethyltransferase 1 (SHMT1) and serine hydroxymethyltransferase 2 (SHMT2), so that the aggregates are degraded, thereby reducing pathological aggregation, and thus ameliorating the pathological condition of patients with neurodegenerative diseases such as ALS and FTD and delaying disease progression. A cofactor and a metabolic substrate of the hydroxymethyltransferase can promote the activity of the hydroxymethyltransferase, thereby enhancing the hydroxymethyl transfer effect on the aggregates such as Poly-GA, Poly-GR and TDP-43, and thus can also be used for treatment of the neurodegenerative diseases such as ALS and FTD.
Resumen de: US20260151515A1
Among the various aspects of the present disclosure is the provision of sigma-1 compounds, their radioligands, and related methods of use. The present teachings include compositions for compounds that target the sigma-1 receptor, as well as their radioligands. The present teachings also include a method to assess treatment efficacy of a sigma-1 modulator in a subject in need, which can include acquiring medical images after administration of a sigma-1 radioligand, characterizing sigma-1 expression from the acquired images, and assessing treatment efficacy of a sigma-1 modulator in the subject based on the assessed sigma-1 expression. The methods can assess treatment efficacy in neurological diseases, including but not limited to Alzheimer's disease.
Resumen de: KR20260081510A
본 발명은 식혜를 유효 성분으로 포함하는 파킨슨 질환을 예방 또는 치료하며 유산균, 레보도파. 도파민 수용제 자극제 및 도파민 분해효소 억제제 등과 병용 투여하여 부작용이 감소하고 치료 효과는 향상하는 파킨슨 질환 개선, 예방 또는 치료용 조성물에 관한 것으로서, 본 발명에 따른 조성물은 신경세포에 대해 신경보호 효능을 가질 뿐만 아니라 파킨슨 질환 동물 모델에 대해 운동능력 및 도파민 전구체 생산에 관여하는 티로신 수산화효소 발현을 향상시키는데 우수한 효과를 나타내므로, 파킨슨 질환의 예방 또는 치료에 유용하게 이용될 수 있다.
Resumen de: US20260151386A1
0000 This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Nº publicación: US20260151390A1 04/06/2026
Solicitante:
CRMH HONG KONG INST OF SCIENCE & INNOVATION CHINESE ACADEMY OF SCIENCES [CN]
CITY UNIV OF HONG KONG [CN]
CRMH, HONG KONG INSTITUTE OF SCIENCE & INNOVATION, CHINESE ACADEMY OF SCIENCES
CITY UNIVERSITY OF HONG KONG
Resumen de: US20260151390A1
The present disclosure provides diazaspiro compounds represented by Formula (I), processes for their preparation, and pharmaceutical uses thereof, all within the field of medicinal chemistry. The diazaspiro compounds disclosed herein function as small-molecule agonists of the cholecystokinin-B receptor (CCK-BR). They exhibit excellent agonistic potency and demonstrate marked selectivity for CCK-BR over the cholecystokinin-A receptor (CCK-AR), thereby mitigating off-target effects and associated adverse reactions. No cardiotoxicity or other safety liabilities have been observed to date. The diazaspiro compounds are contemplated for the prophylaxis or treatment of disorders including, without limitation, epilepsy, depression, dementia, anxiety, Alzheimer's disease, tinnitus, amblyopia, schizophrenia, neuropathic pain, amnesia, gastric hyperacidity, obesity, pancreatic carcinoma, and gallbladder carcinoma.
BOPI
Sede Electrónica
